Case Studies in Multiple Myeloma Care for Challenging Times – Part 1: Newly Diagnosed Multiple Myeloma, Including Treatment Disparities

Please Log In or Register to continue.

Release Date: April 09, 2021
Expiration Date: April 09, 2022

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity on multiple myeloma care for challenging times will include discussion of treatment for newly diagnosed MM, including common regimens; treatment disparities and best practices; and survivorship care plans and practical tools for long-term management and care. Through the case of Bianca - an African American patient with newly diagnosed MM, our faculty will focus on symptom management, infection control, and nursing implications. Please remember to complete part 2 and 3 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.

Target Audience

This activity is designed for nurses and other medical personnel involved in care of patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify common treatment regimens in newly diagnosed and relapsed multiple myeloma
  • Discuss effective symptom management and education of patients with multiple myeloma receiving treatment regimens in the newly diagnosed and relapsed setting
  • Discuss healthcare disparities faced by patients with multiple myeloma who are part of diverse groups, such as African Americans, and identify steps to address barriers to care for underserved populations
  • Describe strategies to support optimizing patient myeloma care through topics such as shared decision making and telehealth techniques


Newly Diagnosed Multiple Myeloma, Including Treatment Disparities

  1. Treatment for newly diagnosed multiple myeloma including common regimens
  2. Treatment disparities and best practices
  3. Survivorship care plans and practical tools for long-term management and care
  4. One case study: Bianca - an African American patient with newly diagnosed multiple myeloma

Instructions for Participation and Credit

This activity is eligible for credit through April 09, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You will be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 100%. You will be able to review the correct answers along with the rationale before completing the program. Please note you must achieve a passing score within 3 attempts or you will be unable to complete the activity and earn CNE credit.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.
  7. Your online certificate will be saved on in your CE Records, which you can access at any time using your login.

Faculty Biographies

Beth Faiman, PhD

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN
Adult Nurse Practitioner
Multiple Myeloma Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Dr. Beth Faiman received a Bachelor of Science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a Master of Science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research and Nursing from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is currently employed as an Adult Nurse Practitioner in the department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio. She is an appointed member in the Cancer Prevention Control and Population Research Program, Case Comprehensive Cancer Center as well as adjunct faculty at Ursuline College, Case Western Reserve University, and Kent State University. Dr. Faiman is the recipient of a many awards including the 2012 Excellence in Medical Oncology, the 2013 Commendation for Patient and Nursing Education Award sponsored by The Oncology Nursing Society, and the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University. She was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016. Additionally, Dr. Faiman was recognized by the American Academy of Nursing for her contributions to healthcare through selection to the American Academy of Nursing in 2019 and was appointed by the American Board of Internal Medicine (ABIM) to ABIM Hematology Specialty Board in July 2019. The ABIM is responsible for governing the licensure of current and future board-certified hem/onc physicians.

Dr. Faiman is an active author, presenter, and educator on the topics of multiple myeloma, amyloidosis, chronic leukemia, plasma cell dyscrasias, and general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is currently Editor-in-Chief of the Journal of the Advanced Practitioner in Oncology (JADPRO), former founding Editor-In-Chief of the Oncology Nurse APN-PA, and former founding editorial board member of ASH Clinical News. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman has served as a prolific speaker, publisher, and committee leader conducting original research for over fourteen years as a distinguished member of the International Myeloma Foundation Nurse Leadership Board.

Amy Pierre, RN

Amy E. Pierre, RN, MSN, ANP-BC
Adult Nurse Practitioner
Multiple Myeloma/Lymphoma Division
Memorial Sloan Kettering Cancer Center
Montvale, NJ
Clinical Director, Flatiron Health
New York, NY

Amy Pierre received a bachelor’s degree in biology at Tufts University in Boston, Massachusetts and a master’s degree in nursing from Yale University School of Nursing in New Haven, Connecticut. While at Yale University, Ms. Pierre’s thesis was focused on the quality of life and health behaviors of African American breast cancer survivors. At Tufts Medical Center, she provided comprehensive medical and psychosocial care of hospitalized patients with life-threatening medical conditions as the lead palliative care nurse practitioner.  Ms. Pierre was instrumental in the development of the palliative care program at Tufts Medical Center and served as a resource and educator for the hospital on all issues related to palliative care. At the John Theurer Cancer Center at Hackensack University Medical Center, Ms. Pierre became one of the nurse leaders in the myeloma division providing comprehensive care to a range of patients with plasma cell dyscrasias.  At Memorial Sloan Kettering in Montvale, NJ, Ms. Pierre serves as the expert hematology nurse practitioner in caring for patients with lymphoma and multiple myeloma.  In her position as a Clinical Director in the Research Oncology division at Flatiron Health, she provides clinical support for the research organization.

Ms. Pierre has coauthored publications in the journals Journal of the Advanced Practitioner in Oncology, Cancer, Clinical Cancer Research, Clinical Journal of Oncology Nursing, and Seminars in Oncology Nursing.  She serves on the Professional Development and Leadership Committee and also the Board of Directors for the Advanced Practitioner Society for Hematology and Oncology (APSHO). Ms. Pierre is on the advisory council to the International Myeloma Foundation’s African American Initiative, an endeavor to tackle the marked racial disparities observed in multiple myeloma, and she is lead author on “African American Patients with Multiple Myeloma: Optimizing Care to Decrease Racial Disparities” in CJON, as well as a chapter entitled: “Care of Special Populations” in Multiple Myeloma: A Textbook for Nurses (3rd ed.) Ms. Pierre serves as a member of the International Myeloma Foundation’s Nurse Leadership Board (NLB), working to improve the nurs­ing care and self-care of patients with myeloma. In her role on the NLB, Ms. Pierre has made valuable contributions to the education of both patients and nurses through educational seminars across the country.


Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

0.5 contact hours may be earned for successful completion of this activity. A total of 1.5 contact hours may be earned by completing all 3 activities in this course.

Accreditor Disclosure of Conflicts of Interest Policy

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure of Conflicts of Interest

It is the policy of the Annenberg Center for Health Sciences at Eisenhower to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, the Annenberg Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are mitigated by the Annenberg Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Faculty Disclosures

The faculty reported the following financial relationships and/or other relationships they have with ineligible organizations related to the content of this CNE/CE activity:

Name of Faculty

Reported Financial Relationship

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN

Consulting with BMS/Celgene, Karyopharm, GSK, Sanofi

Amy E. Pierre, RN, MSN, ANP-BC

Consulting with Oncopeptides & Celgene; Employed by Flatiron Health

Accreditor Disclosures

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant relationships to disclose.

The content and program managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Content or Program Manager

Reported Financial Relationship

Joyce Divine, PhD, MBA

None to disclose

Michelle Faber, MS

None to disclose

Diane Moran, RN, MA, EdM

None to disclose

Maya Ormsby, MS, MBA, MIM

None to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

ONS Disclaimer

A presentation timeslot has been assigned to provide a symposium supported by the International Myeloma Foundation during the Oncology Nursing Society’s (ONS) Congress Virtual Event. The Oncology Nursing Society's assignment of a presentation timeslot does not imply product endorsement.

Provided by the International Myeloma Foundation

Accredited by Annenberg Center for Health Sciences at Eisenhower

This accredited education activity is supported by educational grants from AbbVie Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Karyopharm Therapeutics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Oncopeptides, Inc.; and Sanofi Genzyme.


©2021 International Myeloma Foundation, 12650 Riverside Drive, Suite 206, North Hollywood, CA 91607, USA, Tel: 1-818-487-7455

No portion of this material may be copied or duplicated without the expressed permission of the International Myeloma Foundation.

Please Log In or Register to continue.